Hexagon Bio leverages a genomics-based platform and understanding of natural product evolution to develop next-generationantibody-drug conjugates (ADCs) with novel payloads for cancer. We use data science, genomics, machine learning, synthetic biology, and automation to discover potent, evolutionarily refined small molecules from microbial genomes, and apply medicinal chemistry to optimize these molecules into truly transformative medicines.